Celldex Therapeutics, Inc. (CLDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 20M 40M 60M Q4 '10: 46.8M Q1 '11: 45.6M Q2 '11: 44.6M Q3 '11: 44.6M Q4 '11: 9.3M Q1 '12: 9.2M Q2 '12: 9.2M Q3 '12: 10M Q4 '12: 11.2M Q1 '13: 11.2M Q2 '13: 9.3M Q3 '13: 7.1M Q4 '13: 4.1M Q1 '14: 2.1M Q2 '14: 2.6M Q3 '14: 2.7M Q4 '14: 3.6M Q1 '15: 3.7M Q2 '15: 5.2M Q3 '15: 5.2M Q4 '15: 5.5M Q1 '16: 6.3M Q2 '16: 5.5M Q3 '16: 6.7M Q4 '16: 6.8M Q1 '17: 7M Q2 '17: 9.5M Q3 '17: 11.2M Q4 '17: 12.7M Q1 '18: 15.3M Q2 '18: 14.2M Q3 '18: 11.2M Q4 '18: 9.5M Q1 '19: 6.9M Q2 '19: 4.8M Q3 '19: 4.5M Q4 '19: 3.6M Q1 '20: 4.9M Q2 '20: 4.4M Q3 '20: 4.5M Q4 '20: 7.4M Q1 '21: 5.4M Q2 '21: 8.6M Q3 '21: 8.1M Q4 '21: 4.7M Q1 '22: 4.1M Q2 '22: 824K Q3 '22: 1.1M Q4 '22: 2.4M Q1 '23: 3.1M Q2 '23: 3.3M Q3 '23: 4.4M Q4 '23: 6.9M Q1 '24: 6.1M Q2 '24: 8.3M Q3 '24: 10M Q4 '24: 7M Q1 '25: 7.6M Q2 '25: 5.8M Q3 '25: 2.6M Q4 '25: 1.5M Q1 '26: 866K Q2 '26: 158K Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '11: -43.4M Q1 '12: -47M Q2 '12: -50.6M Q3 '12: -53.9M Q4 '12: -58.1M Q1 '13: -62.2M Q2 '13: -67.4M Q3 '13: -75.9M Q4 '13: -81.4M Q1 '14: -95.5M Q2 '14: -105.4M Q3 '14: -112.5M Q4 '14: -122.4M Q1 '15: -121.9M Q2 '15: -126.1M Q3 '15: -128.2M Q4 '15: -129.5M Q1 '16: -134.3M Q2 '16: -133.9M Q3 '16: -131.5M Q4 '16: -132.9M Q1 '17: -132.3M Q2 '17: -128.9M Q3 '17: -130.9M Q4 '17: -121.5M Q1 '18: -206.1M Q2 '18: -194M Q3 '18: -169.8M Q4 '18: -156.4M Q1 '19: -54.7M Q2 '19: -50.1M Q3 '19: -54.2M Q4 '19: -55M Q1 '20: -50M Q2 '20: -49.1M Q3 '20: -51.6M Q4 '20: -63.4M Q1 '21: -67.1M Q2 '21: -69.2M Q3 '21: -75.7M Q4 '21: -71.2M Q1 '22: -77.9M Q2 '22: -100.8M Q3 '22: -107.7M Q4 '22: -115.2M Q1 '23: -124.4M Q2 '23: -121.3M Q3 '23: -134.8M Q4 '23: -154.5M Q1 '24: -162.7M Q2 '24: -175.8M Q3 '24: -186.7M Q4 '24: -195.1M Q1 '25: -217.2M Q2 '25: -234.7M Q3 '25: -256.2M Q4 '25: -287.4M Q1 '26: -309.1M Q2 '26: -325.8M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '11: -44.8M Q1 '12: -48.3M Q2 '12: -51.8M Q3 '12: -55M Q4 '12: -59.1M Q1 '13: -62.9M Q2 '13: -68.2M Q3 '13: -76.3M Q4 '13: -81.5M Q1 '14: -94.1M Q2 '14: -103.4M Q3 '14: -108.3M Q4 '14: -118.1M Q1 '15: -118.4M Q2 '15: -122.4M Q3 '15: -126.3M Q4 '15: -127.2M Q1 '16: -131.7M Q2 '16: -131.3M Q3 '16: -128.9M Q4 '16: -128.5M Q1 '17: -128.1M Q2 '17: -124.7M Q3 '17: -121.5M Q4 '17: -93M Q1 '18: -176.9M Q2 '18: -164.7M Q3 '18: -145.6M Q4 '18: -151.2M Q1 '19: -50.3M Q2 '19: -45.7M Q3 '19: -49.8M Q4 '19: -50.9M Q1 '20: -46.3M Q2 '20: -45.5M Q3 '20: -48.3M Q4 '20: -59.8M Q1 '21: -63.7M Q2 '21: -66M Q3 '21: -72.3M Q4 '21: -70.5M Q1 '22: -77M Q2 '22: -99.7M Q3 '22: -106M Q4 '22: -112.3M Q1 '23: -118.6M Q2 '23: -113.1M Q3 '23: -124.6M Q4 '23: -141.4M Q1 '24: -144.9M Q2 '24: -150.2M Q3 '24: -154.1M Q4 '24: -157.9M Q1 '25: -178.9M Q2 '25: -199.6M Q3 '25: -224.5M Q4 '25: -258.8M Q1 '26: -283.6M Q2 '26: -300.5M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '11: -32.3M Q4 '11: -35.7M Q1 '12: -40.3M Q2 '12: -42.9M Q3 '12: -45.8M Q4 '12: -49.8M Q1 '13: -53.4M Q2 '13: -59.5M Q3 '13: -66M Q4 '13: -67.7M Q1 '14: -82.3M Q2 '14: -85.1M Q3 '14: -94.3M Q4 '14: -101.5M Q1 '15: -102.3M Q2 '15: -106.2M Q3 '15: -107.4M Q4 '15: -98.9M Q1 '16: -101.2M Q2 '16: -110.3M Q3 '16: -106.4M Q4 '16: -113M Q1 '17: -113.4M Q2 '17: -100.4M Q3 '17: -100.8M Q4 '17: -99.9M Q1 '18: -92.7M Q2 '18: -89.3M Q3 '18: -79.3M Q4 '18: -75.2M Q1 '19: -60.4M Q2 '19: -54.1M Q3 '19: -50.8M Q4 '19: -46.4M Q1 '20: -45.3M Q2 '20: -45.5M Q3 '20: -46.2M Q4 '20: -40.4M Q1 '21: -46.4M Q2 '21: -47.1M Q3 '21: -51.6M Q4 '21: -60.9M Q1 '22: -67.4M Q2 '22: -77.7M Q3 '22: -96.5M Q4 '22: -103.7M Q1 '23: -107.8M Q2 '23: -112.7M Q3 '23: -96.5M Q4 '23: -107.3M Q1 '24: -119.4M Q2 '24: -121.5M Q3 '24: -157.8M Q4 '24: -157.8M Q1 '25: -171.5M Q2 '25: -186.2M Q3 '25: -179.5M Q4 '25: -210.9M Q1 '26: -222.2M Q2 '26: -235.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '11: -33.1M Q4 '11: -36.2M Q1 '12: -40.7M Q2 '12: -43.3M Q3 '12: -46.1M Q4 '12: -50.1M Q1 '13: -53.9M Q2 '13: -60.6M Q3 '13: -68M Q4 '13: -71.9M Q1 '14: -86.6M Q2 '14: -89.5M Q3 '14: -98.4M Q4 '14: -103.5M Q1 '15: -105.5M Q2 '15: -110.1M Q3 '15: -112M Q4 '15: -103.8M Q1 '16: -105.1M Q2 '16: -113.3M Q3 '16: -109M Q4 '16: -115.8M Q1 '17: -116M Q2 '17: -103.1M Q3 '17: -103M Q4 '17: -101.7M Q1 '18: -94.4M Q2 '18: -90.4M Q3 '18: -80.2M Q4 '18: -76M Q1 '19: -61.2M Q2 '19: -54.8M Q3 '19: -51.6M Q4 '19: -47.1M Q1 '20: -46.1M Q2 '20: -46.9M Q3 '20: -47.6M Q4 '20: -42M Q1 '21: -48.3M Q2 '21: -48.2M Q3 '21: -52.7M Q4 '21: -62.2M Q1 '22: -68.6M Q2 '22: -79.5M Q3 '22: -98.4M Q4 '22: -105.6M Q1 '23: -109.6M Q2 '23: -114.3M Q3 '23: -97.9M Q4 '23: -109.1M Q1 '24: -120.9M Q2 '24: -122.9M Q3 '24: -159.7M Q4 '24: -159.7M Q1 '25: -173.4M Q2 '25: -188.5M Q3 '25: -181.7M Q4 '25: -213.7M Q1 '26: -226.2M Q2 '26: -242.1M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '10: 31.8M Q3 '10: 31.9M Q1 '11: 32M Q2 '11: 37.5M Q3 '11: 44.1M Q1 '12: 50.1M Q1 '21: 39.6M Q2 '21: 39.6M Q3 '21: 45.5M Q1 '22: 46.7K Q2 '22: 46.8K Q3 '22: 46.9K Q1 '23: 47.2K Q2 '23: 47.3K Q3 '23: 47.3K Q1 '24: 58.9K Q2 '24: 66K Q3 '24: 66.3K Q1 '25: 66.4M Q2 '25: 66.4M Q3 '25: 66.4K Q1 '26: 66.6M Q2 '26: 77.8M Q3 '10 Q3 '11 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '11: -1.14 Q1 '12: -1.10 Q2 '12: -1.06 Q3 '12: -1.04 Q4 '12: -1.02 Q1 '13: -0.98 Q2 '13: -0.99 Q3 '13: -1.03 Q4 '13: -1.03 Q1 '14: -1.13 Q2 '14: -1.21 Q3 '14: -1.23 Q4 '14: -1.32 Q1 '15: -1.32 Q2 '15: -1.33 Q3 '15: -1.34 Q4 '15: -1.31 Q1 '16: -1.33 Q2 '16: -1.32 Q3 '16: -1.29 Q4 '16: -1.26 Q1 '17: -1.19 Q2 '17: -1.10 Q3 '17: -1.01 Q4 '17: -1.13 Q1 '18: -13.46 Q2 '18: -14.90 Q3 '18: -15.36 Q4 '18: -15.75 Q1 '19: -4.54 Q2 '19: -3.71 Q3 '19: -3.80 Q4 '19: -3.63 Q1 '20: -2.96 Q2 '20: -2.62 Q3 '20: -2.23 Q4 '20: -2.14 Q1 '21: -1.83 Q2 '21: -1.67 Q3 '21: -1.76 Q4 '21: -1.64 Q4 '12 Q2 '14 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.